NCT07119515 Teletherapy vs. In-Person Cognitive Behavioral Therapy for Generalized Anxiety Disorder
| NCT ID | NCT07119515 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Government College University Faisalabad |
| Condition | Generalized Anxiety Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2025-03-10 |
| Primary Completion | 2025-08-26 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 25 participants in total. It began in 2025-03-10 with a primary completion date of 2025-08-26.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized controlled trial is to compare the clinical efficacy of teletherapy versus in-person third-wave cognitive behavioral therapy (CBT) in treating generalized anxiety disorder (GAD) among young individuals aged 18-45 years in Pakistan. The main questions it aims to answer are: * Is teletherapy as effective as in-person therapy in reducing anxiety symptoms and stress? * Do therapeutic alliance, treatment adherence, and social support influence treatment outcomes differently across delivery methods? Researchers will compare the teletherapy group (remote sessions via digital platforms) and the in-person therapy group (face-to-face sessions) to evaluate differences in symptom reduction, general health improvement, and moderating factors like therapeutic alliance. Participants will: * Undergo a 8-week intervention with weekly structured third-wave CBT sessions. * Complete assessments at baseline, post-intervention, and follow-up using validated scales (e.g., Generalized Anxiety Disorder-7 \[GAD-7\], Hamilton Anxiety Rating Scale \[HAM-A\]). * Engage in modules including mindfulness, behavioral activation, and exposure therapy, adapted for their assigned delivery method. This study aims to address gaps in mental health accessibility in Pakistan by evaluating whether teletherapy can serve as a viable alternative to traditional in-person care.
Eligibility Criteria
Inclusion Criteria: * age ≥18-≤45 years -meeting the diagnostic criteria according to DSM-5 TR -ability to understand and read English -ability to use digital technology and having access to the Internet -signed an informed consent form Exclusion Criteria: * the presence of risk of suicide and self-destructive behaviors -presence of another severe mental disorder (i.e., substance abuse, psychotic disorder, or bipolar disorder) -presence of severe personality disorder -presence of a medical condition whose severity or characteristics prevent participation in treatment -receiving another psychological treatment during the study * an increase or change in medication during the study period
Contact & Investigator
Imaan Sabeeh, MS Scholar
PRINCIPAL INVESTIGATOR
Government College University Faisalabad
Frequently Asked Questions
Who can join the NCT07119515 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Generalized Anxiety Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07119515 currently recruiting?
Yes, NCT07119515 is actively recruiting participants. Contact the research team at imaansabeeh@gmail.com for enrollment information.
Where is the NCT07119515 trial being conducted?
This trial is being conducted at Faisalabad, Pakistan.
Who is sponsoring the NCT07119515 clinical trial?
NCT07119515 is sponsored by Government College University Faisalabad. The principal investigator is Imaan Sabeeh, MS Scholar at Government College University Faisalabad. The trial plans to enroll 25 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.